Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Lamivudine for chronic hepatitis B.

¹Alice Ho Miu Ling Nethersole Hospital, The Chinese University of Hong Kong, Hong Kong SAR. nancyleung@cuhk.edu.hk.

Expert Review of Anti-Infective Therapy

|October 16, 2004

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Erratum to: Mutational analysis of 65 Wilson disease patients in Hong Kong Chinese: Identification of 17 novel mutations and its genetic heterogeneity.

Journal of human genetics·2020

Same author

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.

Hepatology (Baltimore, Md.)·2011

Same author

Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance.

Hepatology international·2011

Same author

Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B.

Liver international : official journal of the International Association for the Study of the Liver·2011

Same author

Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.

Liver international : official journal of the International Association for the Study of the Liver·2011

Same author

Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study.

The Korean journal of hepatology·2010

Lamivudine is a hepatitis B treatment, but drug resistance is a significant problem. Resistance mutants emerge annually, potentially causing hepatitis relapse and liver decompensation.

Area of Science:

Hepatology
Virology
Pharmacology

Background:

Lamivudine (Epivir) was FDA-approved in 1998 for chronic hepatitis B.
It offers benefits to select patients but faces challenges.

Purpose of the Study:

To review the efficacy and challenges of lamivudine therapy for chronic hepatitis B.
To discuss the emergence and implications of drug resistance.

Main Methods:

Review of existing literature on lamivudine treatment for chronic hepatitis B.
Analysis of data regarding drug resistance rates and clinical outcomes.

Main Results:

Drug resistance emerges in 15-30% of patients annually.
Lamivudine resistance is linked to hepatitis relapse and hepatic decompensation.

Related Experiment Videos

Conclusions:

Guidelines now position lamivudine as first-line therapy for HBeAg-positive chronic hepatitis B.
Its use in HBeAg-negative patients remains a subject of debate.